



## **TScan Therapeutics Announces Presentations at Upcoming Conferences**

November 9, 2020

WALTHAM, Mass.-(BUSINESS WIRE)-TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced that management will present virtually at the following upcoming medical meeting and healthcare conferences:

### **The Society for Immunotherapy of Cancer Annual Meeting (SITC)**

- Gavin MacBeath, Ph.D., Chief Scientific Officer, will present an e- poster entitled “Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy”. The poster will be available for viewing in the Virtual Poster Hall on Monday, November 9, 2020, at 8:00 a.m. Eastern Time.

### **Jefferies London Global Healthcare Conference**

- David Southwell, Chief Executive Officer, will present a company overview on Thursday, November 19, 2020, at 10:50 a.m. Eastern Time.

### **3rd Annual Evercore ISI HealthCONx Conference**

- Mr. Southwell will participate in a panel discussion entitled “Finders Keepers: Identifying New Cancer Targets with Atreca, TScan Therapeutics” on Wednesday, December 2, 2020, at 10:30 a.m. Eastern Time.

### **About TScan Therapeutics**

TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off-target effects. Lead program TSC-100 is expected to enter clinical development for liquid cancers in 2021, and the Company is advancing additional TCR-Ts for solid cancers. TScan was co-founded by Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Women's Hospital. The Company has raised over \$80 million to date from leading strategic collaborators and investors including Longwood Fund, Novartis Institutes for Biomedical Research, Astellas Venture Management, Novartis Venture Fund, Bessemer Venture Partners, GV, 6 Dimensions Capital, and Pitango Venture Capital.

### **Contacts**

#### **Media Contact:**

David Rosen  
Argot Partners  
212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

#### **Investor Contact:**

Sherri Spear  
Argot Partners  
212-600-1902  
[sherri@argotpartners.com](mailto:sherri@argotpartners.com)